Followers | 145 |
Posts | 27556 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Tuesday, April 21, 2020 11:01:00 AM
PR Newswire PR Newswire•April 21, 2020
- Wize Pharma owns 8.9% of Bonus BioGroup
- Bonus BioGroup's mesenchymal stromal cell (MSC)-based drug MesenCure intended to treat acute and life-threatening respiratory distress resulting from COVID-19 and other causes targeting a potential current market of over 1 billion patients
HOD HASHARON, Israel, April 21, 2020 /PRNewswire/ -- Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that Bonus BioGroup (TASE: BONS.TA), a company in which Wize owns 8.9% of its equity securities, has initiated a preclinical study of its drug product candidate MesenCure, specifically developed to potentially treat acute and life-threatening respiratory distress and pneumonia whether as a result of infection with coronavirus (COVID-19), or any other type of virus, bacterial infection, or exposure to other contaminants.
MesenCure consists of activated mesenchymal stromal cells (MSCs) that are isolated from the adipose tissue of healthy donors. Following intravenous transfusion, the activated cells are expected to reach the lungs and act to reduce inflammation, and alleviate respiratory and other symptoms. Bonus BioGroup has more than a decade of MSC-related experience, patented technologies, and in-house MSC manufacturing capacity based on the development of its lead clinical stage BonoFill™, a tissue-engineered bone graft product.
Bonus BioGroup has reported that preliminary efficacy data from the MesenCure study are expected in May 2020, with study completion anticipated in the third quarter of 2020.
MesenCure may be useful for treating a variety of indications, such as lower respiratory tract infections, acute respiratory distress syndrome, asthma, and chronic obstructive pulmonary disease. According to the Forum of International Respiratory Societies, more than 1 billion people are suffering from inflammatory diseases of the lower respiratory tract worldwide, which cause an estimated 7.5 million deaths each year, and are the third leading cause of death in Europe, not including COVID-19 mortality data.
"Bonus BioGroup's MesenCure, specifically developed to potentially treat the respiratory complications of COVID-19. Moreover, MesenCure addresses the broader need for an effective treatment for millions of patients each year suffering from inflammatory diseases of the lower respiratory tract,," stated Noam Danenberg, CEO of Wize.
About Bonus BioGroup
Bonus BioGroup is an Israeli biotechnology company whose highly innovative, proprietary therapeutic platform for healing severe bone defects is strongly positioned to break into the $8 billion global bone rehabilitation market. The company's BonoFill™ solution which employs novel tissue engineering technology for growing live human bone grafts has been selected by the Israeli Ministry of Science as a technology that will change the world forever, and it is already achieving outstanding success rates in Phase I/II clinical trials. The BonoFill™ solution is a revolutionary approach for personalized treatment of bone defects using live bone grafts created from the patient's own cells. Patients undergo a simple liposuction procedure to harvest fat tissue, which is then engineered into bone using Bonus BioGroup's proprietary technology. Upon injection into the bone defect, the bone graft grows, connects and matures to become healthy new autologous bone, while reducing the risk of rejection.
https://finance.yahoo.com/news/wize-pharmas-strategic-transaction-partner-130000675.html
Recent MIGI News
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for March 2024 • GlobeNewswire Inc. • 04/18/2024 11:00:53 AM
- Mawson Infrastructure Group Inc. Announces New Board Chair • GlobeNewswire Inc. • 04/15/2024 09:15:22 PM
- Mawson Infrastructure Group Inc. Reports Q4 and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 04/01/2024 10:05:07 AM
- Mawson Infrastructure Group Expands Co-Location Business • GlobeNewswire Inc. • 03/27/2024 12:50:58 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for February 2024 • GlobeNewswire Inc. • 03/19/2024 12:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 01:00:38 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/07/2024 02:43:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:25:47 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 02:37:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 10:16:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 01:50:55 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for January 2024 • GlobeNewswire Inc. • 02/16/2024 01:45:24 PM
- Mawson Infrastructure Group Inc. Executes Another Customer Co-Location Agreement • GlobeNewswire Inc. • 02/06/2024 02:00:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:50:32 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for December 2023 • GlobeNewswire Inc. • 01/16/2024 01:45:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 10:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:15:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:37:03 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for November 2023 • GlobeNewswire Inc. • 12/20/2023 09:35:29 PM
- Mawson Infrastructure Group Inc. Executes New Customer Co-Location Agreement • GlobeNewswire Inc. • 12/19/2023 10:11:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/24/2023 06:52:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/24/2023 06:52:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/24/2023 06:52:03 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM